The Global Anticoagulant Registry in the Field-Atrial Fibrillation (GARFIELD-AF) examined
real-world practice in a total of 57,149 (5069 retrospective, 52,080 prospective) patients with …

Atrial fibrillation is the most common arrhythmia. It increases the risk of thromboembolism by
up to fivefold. Guidelines provide evidence-based recommendations to effectively mitigate …

Background Since non-vitamin K antagonist oral anticoagulants (NOACs) do not require
coagulation monitoring, concerns of lower adherence and persistence to NOACs than …

Aim Non‐vitamin K antagonist oral anticoagulants (NOACs) are increasingly preferred over
vitamin K antagonists (VKAs) in atrial fibrillation (AF) management. However, differences in …

Introduction Stroke prevention using oral anticoagulation (OAC) is the first management
priority in atrial fibrillation (AF). Despite the importance of good therapy adherence, real …

Aims To analyse the appropriateness of direct oral anticoagulant (DOAC) dosing and
determinants for under‐and overdosing as well as acceptance and implementation rates of …

There is a need to reassess contemporary oral anticoagulation (OAC) trends and barriers
against guideline directed therapy in the United States. Most previous studies were …

Introduction The use of direct oral anticoagulants (DOAC) is increasing. Specific
concentrations are available and have been proven to be reliable and reproducible in …

Aim. To evaluate the prevalence of oral anticoagulant therapy at the outpatient and inpatient
stages in patients hospitalized with ischemic stroke. Material and methods. This open …

Context Since the introduction of direct oral anticoagulants (DOACs) for the treatment of
nonvalvular atrial fibrillation (Afib), oral anticoagulants (OACs) prescription has evolved. Aim …